Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)
Lithium
45.28
0.49%
Gold
2,672.30
0.71%
Copper
4.12
(0.88%)
Oil
69.80
1.1%
Bitcoin
97,547.09
3.39%
FTSE 100
8,088.21
0.04%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,408.47
0.26%
Iron Ore
102.30
1.26%
USD/AUD
0.65
0.06%
Hang Seng
19,601.11
(0.23%)

Race Oncology Ltd

RAC

ASX

Race Oncology (RAC), an Australian-based clinical-stage biopharmaceutical company, is driven by a dedicated mission to be at the forefront of advancements in cancer care. They focus on developing innovative therapies that target not only the eradication of cancer but also the well-being of patients throughout treatment.

Latest Posts

Line Chart with Gradient
Price
$1.430
0 (0%)
At Close 20/11 (AEST)
Related Companies
PROBIOTEC LIMITED
$PBP
IMMURON LIMITED
$IMC
EPSILON HEALTHCARE LIMITED
$EPN
NYRADA INC.
$NYR
TISSUE REPAIR LTD
$TRP

Leave a Comment on RAC


Comments for RAC

    Latest Posts

    race-oncology-asx-rac-announces-board-renewal-completion-rac
    Health Care $RAC

    Race Oncology (ASX: $RAC) announces board renewal completion

    Dr Pete Smith appointed as Executive Chair, Dr Daniel Tillett as Managing Director & CEO, and Dr Serge Scrofani joins as Independent Non-Executive Director

    September 2, 2024
    race-oncology-asx-rac-appoints-george-clinical-to-support-phase-1a-1b-trial-rac
    Health Care $RAC

    Race Oncology (ASX: $RAC) appoints george clinical to support phase 1a/1b trial

    George Clinical International appointed to support clinical development of RC220 bisantrene in solid tumour patients

    June 20, 2024
    race-oncology-asx-rac-secures-us-fda-rare-paediatric-disease-designation-for-rc220-bisantrene-rac
    Health Care $RAC

    Race Oncology (ASX: $RAC) secures US FDA rare paediatric disease designation for RC220 bisantrene

    US FDA designation enables potential for lucrative Priority Review Voucher

    June 18, 2024
    race-oncology-asx-rac-completes-cgmp-manufacturing-for-bisantrene-formulation-rc220-rac
    Health Care $RAC

    Race Oncology (ASX: $RAC) completes cGMP manufacturing for bisantrene formulation RC220

    Certificate of Analysis confirms RC220 meets cGMP specifications for human IV drug product

    March 26, 2024
    race-oncology-asx-rac-presents-potent-anticancer-activity-in-aml-models-rac
    Health Care $RAC

    Race Oncology (ASX: $RAC) presents potent anticancer activity in AML models

    Bisantrene exhibits robust anticancer synergy in AML models

    March 6, 2024
    race-oncology-asx-rac-receives-4-0m-rd-tax-refund-rac
    Health Care $RAC

    Race Oncology (ASX: $RAC) receives $4.0m r&d tax refund

    Australian biopharmaceutical company to utilize funds for clinical development of bisantrene in 2024

    February 27, 2024

    RAC

    $RAC

    Race Oncology (ASX: $RAC) announces board renewal completion

    Dr Pete Smith appointed as Executive Chair, Dr Daniel Tillett as Managing Director & CEO, and Dr Serge Scrofani joins as Independent Non-Executive Director

    RAC

    $RAC

    Race Oncology (ASX: $RAC) appoints george clinical to support phase 1a/1b trial

    George Clinical International appointed to support clinical development of RC220 bisantrene in solid tumour patients

    RAC

    $RAC

    Race Oncology (ASX: $RAC) secures US FDA rare paediatric disease designation for RC220 bisantrene

    US FDA designation enables potential for lucrative Priority Review Voucher

    RAC

    $RAC

    Race Oncology (ASX: $RAC) completes cGMP manufacturing for bisantrene formulation RC220

    Certificate of Analysis confirms RC220 meets cGMP specifications for human IV drug product

    RAC

    $RAC

    Race Oncology (ASX: $RAC) presents potent anticancer activity in AML models

    Bisantrene exhibits robust anticancer synergy in AML models

    RAC

    $RAC

    Race Oncology (ASX: $RAC) receives $4.0m r&d tax refund

    Australian biopharmaceutical company to utilize funds for clinical development of bisantrene in 2024

    Related Companies
    ECOFIBRE LIMITED
    $EOF
    AUSCANN GROUP HOLDINGS LTD
    $AC8
    IMUGENE LIMITED
    $IMU
    INVEX THERAPEUTICS LTD
    $IXC
    TELIX PHARMACEUTICALS LIMITED
    $TLX

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions